Home › Trials › NCT07648160
Clinical trial Recruiting at 1 site Interventional Ages 18 and up

IV contrast-enhanced CBCT with HyperSight for image guidance in advanced cancer radiotherapy

Official title: Contrast-enhanced CBCT With C-arm HyperSight Technology: A Feasibility Study

Run by University Health Network, Toronto · NCT07648160 · Data updated 2026-11-12

This study tests whether giving IV contrast during cone-beam CT helps doctors see the tumor better during radiotherapy in people with advanced cancer.

More Advanced Cancer trials

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment20 (estimated)
SponsorUniversity Health Network, Toronto
Academic / other
Drugs / interventionsradiation
Locations1 site (Toronto, Ontario)
StatusRecruiting
StartedJune 24, 2026
Main results expectedJuly 1, 2027
Study endsJuly 1, 2027
Registry record updatedJune 26, 2026
Trial IDNCT07648160 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Patients with biopsy-proven cancer planning to receive spatially fractionated radiotherapy and who can consent, have normal kidney function, and meet MRI compatibility criteria.

Probably not a fit

Patients with contraindications to iodinated contrast, known renal disease, or inability to undergo MRI may not receive benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a single-arm feasibility study evaluating intravenous contrast-enhanced cone-beam CT (IV-CBCT) for image guidance in radiotherapy. Participants will undergo planning imaging with fMRI and mpMRI, then receive IV-contrast enhanced CBCT during their second and final treatment fractions, along with standard daily CBCT. The aim is to determine feasibility and tolerability of IV-contrast CBCT and whether it improves target visibility during treatment with HyperSight-enabled TrueBeam. Enrollment is limited to patients scheduled for spatially fractionated radiation therapy who can provide informed consent.

Why it matters

Potential benefit: If successful, IV-contrast CBCT could improve target delineation and treatment accuracy during radiotherapy.

How similar studies have gone: Previous work in contrast-enhanced imaging for radiotherapy guidance has shown feasibility in select settings, but this exact approach with HyperSight CBCT is being explored for novelty.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Primary biopsy-proven cancer
* Planning to undergo spatially fractionated radiation therapy
* Able to provide informed consent
* Willingness to participate in follow-up
* ECOG less than or equal to 3
* Normal creatinine (below 109mmol/L), normal eGF

Exclusion Criteria:

* Unable to understand/provide consent
* History of allergic reaction to iodinated IV contrast dye (allergy to MR contrast is not an exclusion criteria)
* Known renal disease
* Single kidney
* Kidney transplant
* Dialysis
* Contraindication to MRI

Where it's running

  • Princess Margaret Cancer Center
    Toronto, Ontario, Canada     Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Advanced Cancer 146University Health Network, Toronto 216
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.